Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: Long-acting stimulant and nonstimulant treatments

American Journal of Managed Care

Volumn 10, Issue SUPPL. 6, 2004, Pages

  Stein, Mark A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; CENTRAL STIMULANT AGENT; DEX SPAN; DEXAMPHETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; PEMOLINE MAGNESIUM; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ANOREXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR MODIFICATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; IRRITABILITY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DIFFUSION OF INNOVATION; FEMALE; HUMANS; MALE; TREATMENT OUTCOME; UNITED STATES;

EID: 3242759031     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Weiss G, Hechtman L. Hyperactive Children Grown Up. New York: Wiley; 1986.
2. Zametkin AJ. Attention-deficit disorder. Born to be hyperactive? JAMA. 1995;273:1871-1874.
3. Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol. 2002;30:463-475.
4. Hallowell EM, JJ Ratey. Driven to Distraction. 1st ed. New York, NY: Pantheon Books; 1994.
5. Leibson CL, Long KH. Economic implications of attention-deficit hyperactivity disorder for healthcare systems. Pharmacoeconomics. 2003;21:1239-1262.
6. Bradley C. The behavior of young children receiving benzedrine. Am J Psychiatry. 1937;94:577-585.
7. Swanson J. Effects of stimulant medication on hyperactive children: a review of reviews. Exceptional Children. 1993;60:154-162.
8. Conners CK. Forty years of methylphenidate treatment in attention-deficit/hyperactivity disorder. J Atten Disord. 2002;6(suppl 1):S17-S30.
9. Castellanos FX, Acosta MT. [Tourette syndrome: an analysis of its comorbidity and specific treatment.] Rev Neurol. 2004;38(suppl 1):124-130. Spanish.
10. Ella J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatment of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36:141-155.
11. Rapport MD, Denney C, DuPaul GJ, Gardner MJ. Attention deficit disorder and methylphenidate normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry. 1994;33:882-893.
12. Pelham WE, Aronoff HR, Midlam JR, et al. A comparison of Ritalin and Adderall: efficacy and time-course in children with attention-deficit/ hyperactivity disorder. Pediatrics. 1999;103:e43.
13. Fitzpatrick PA, Klorman R, Brumaghim TJ, Borgstedt AD. Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1992;31: 226-234.
14. Pelham WE Jr, Sturges J, Hoza J. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics. 1987;80:491-501.
15. Pelham WE Jr, Greenslade KE, Vodde-Hamilton M. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics. 1990;86:226-237.
16. Rosh JR, Dellert SF, Narkewicz M, Birnbaum A, Whitington G. Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis. Pediatrics. 1998;101:921-923.
17. Greenhill L, Abikoff HB, Arnold EL, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996;35:1304-1313.
18. Kent JD, Blader JC, Koplewicz HS, Abikoff H, Foley CA. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics. 1995;96:320-325.
19. Stein MA, Blondis TA, Schnitzler ER. Methylphenidate dosing: twice daily versus three times daily. Pediatrics. 1996;98:748-756.
20. A 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study in Children with ADHD. Arch Gen Psychiatry. 1999;56: 1073-1086.
21. Greenhill LL, Swanson JM, Vitiello B. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180-187.
22. Jensen PS, Kettle L, Roper MT. Are stimulants over-prescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry. 1999;38:797-804.
23. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40:168-179.
24. Spencer T, Biederman J. Non-stimulant treatment for attention-deficit/ hyperactivity disorder. J Atten Disord. 2002;6(suppl 1):S109-S119.
25. Alderton HR. Tricyclic medication in children and the QT interval: case report and discussion. Can J Psychiatry. 1995;40:325-329.
26. Wilens TE, Biederman J, Baldessarini RJ, Paopolo PR, Flood JG. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32:798-804.
27. Swanson JM, Gupta S, William SL, Agler D, Lerner M, Wigal S. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry. 2002;41:1306-1314.
28. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60:204-211.
29. Swanson JM, Wigel SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004;113:e206-e216.
30. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258-266.
31. Spencer T, Lopez FA, Boellner SW, Chandler MD. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998;155:693-695.
32. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002;63(suppl 12):50-55.
33. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
34. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention deficit hyperactivity disorder. Pediatrics. 2001;108:883-892.
35. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:e105.
36. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112:e404.
37. Greenhill LL, Findling RL, Swanson JM; ADHD Study Group. A double-blind, placebo controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;109:e39.
38. Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs. 2003;5:545-555.
39. Chronis AM, Pelham WE Jr, Gnagy EM, Roberts JE, Aronoff HR. The impact of late-afternoon stimulant dosing for children with ADHD on parent and parent-child domains. J Clin Child Adolesc Psychol. 2003;32:118-126.
40. Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics. 1993;92:212-218.
41. Cox OJ, Merkel RL, Penberth JK, et al. Impact of methylphenidate delivery profiles on driving performance of adolescents with ADHD: a pilot study. J Am Acad Child Adolesc Psychiatry. 2004;43:269-275.
42. McKeage K, Scott LJ. SLI-381 (Adderall XR). CNS Drugs. 2003;17:669-675, discussion 676-677.
43. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.
44. Spencer T, Heiligenstein JH, Biederman J. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147.
45. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
46. Jensen PS, Flinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40:147-158.
47. Klein RG. The role of methylphenidate in psychiatry. Arch Gen Psychiatry. 1995;52:429-433.
48. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S-49S.
49. Gucuyener K, Erdemoglu AD, Senol S, Serdaroglu A, Soysal S, Kochar AI. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol. 2003;18:109-112.
50. Kurlan R. Tourette's syndrome: are stimulants safe? Curr Neurol Neurosci Rep. 2003;4:285-288.
51. Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 1999;38:944-951.
52. Galanter CA, Carlson GA, Jensen PS, et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J Child Adolesc Psychopharmacol. 2003;13:123-136.
53. Charach AA, Ickowicz, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004;43:559-567.
54. Sarampote CS, Efron LA, Robb AS, Pearl PL, Stein MA. Can stimulant rebound mimic pediatric bipolar disorder? J Child Adolesc Psychopharmacol. 2002; 12:63-67.
55. Arnold L. Methylphenidate vs amphetamine: comparative review. J Atten Disorder. 2000;3:200-211.
56. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002;22:468-473.
57. Heil SH, Holmes HW, Bichel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67: 149-156.